SEC Company Response from Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Jul 17, 2017
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: July 17, 2017 · CIK: 0001130166 · Accession: 0001571049-17-006729
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218305
Letter
CYCLACEL PHARMACEUTICALS, INC.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
July 17, 2017
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director
Johnny Gharib
Re: Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed on May 26, 2017, as amended on June 30, 2017, July 6, 2017 and July 17, 2017
File No. 333-218305
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-1 be accelerated to Monday, July 17, 2017, at 5:15 p.m., EST, or as soon as thereafter practicable.
Any questions should be addressed to Joel I. Papernik, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York, telephone (212) 692-6774.
Thank you for your attention to this matter.
Very truly yours,
Cyclacel Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CYCLACEL PHARMACEUTICALS, INC.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
July 17, 2017
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes, Assistant Director
Johnny Gharib
Re: Cyclacel Pharmaceuticals,
Inc.
Registration Statement on Form S-1
Filed on May 26, 2017, as amended on June 30, 2017, July 6, 2017 and July 17, 2017
File No. 333-218305
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations
promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Company”) hereby requests
that the effectiveness of the above-captioned Registration Statement on Form S-1 be accelerated to Monday, July 17, 2017, at 5:15
p.m., EST, or as soon as thereafter practicable.
Any questions should be
addressed to Joel I. Papernik, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue,
New York, New York, telephone (212) 692-6774.
Thank you for your attention to this
matter.
Very truly yours,
Cyclacel Pharmaceuticals, Inc.
/s/ Spiro Rombotis
Spiro
Rombotis
Chief Executive Officer
cc: Securities and Exchange Commission
Suzanne Hayes
Johnny Gharib
Erin Jaskot
Cyclacel Pharmaceuticals, Inc.
Paul McBarron